CWP is currently recruiting patients to a wide range of mental health research studies and drug trials. These are done in collaboration with other NHS Trusts, universities and pharmaceutical companies.
Lived experience
CWP aims to bring together the Trust and people with lived-experience of mental illness and learning disabilities (service users, carers and volunteers). This is particularly important when it comes to research. Service users, carers and volunteers are the experts when it comes to their needs. Their ideas about the things that need to be researched are crucial to make sure that research is meaningful and can be applied to the real world.
If you would like to participate or have a patient who would like to take part on any of our current studies below, please email cwp.
Alternatively, you can print our Invitation to take part in research leaflet, add your details and post it back to us.
Current studies:
Diamonds (Diabetes and Mental Health) - Improving diabetes self- management for people with severe mental illness
|
This trial aims to investigate the clinical and cost-effectiveness of the DIAMONDS intervention for people with serious mental illness. The DIAMONDS intervention is a tailored, support programme to help people with type 2 diabetes and SMI self-manage diabetes.The trial is funded by the National Institute for Health and Care Research (RP-PG-1016-20003); it is sponsored and managed by the University of York. This trial aims to investigate the clinical and cost-effectiveness of the DIAMONDS intervention for people with serious mental illness. The DIAMONDS intervention is a tailored, support programme to help people with type 2 diabetes and SMI self-manage diabetes.The trial is funded by the National Institute for Health and Care Research (RP-PG-1016-20003); it is sponsored and managed by the University of York. |
Diamonds Patient Information Sheet
|
DPIM - Genetics of Mental Illness
|
DPIM is studying large numbers of people with psychiatric disorders to compare the frequency of DNA polymorphisms with people who do not have any history of psychiatric disorders. DPIM is investigating responsiveness to drug treatments and test whether genetic polymorphisms can predict who responds to which treatment.
Aim: To understand the causes of different psychiatric disorders and to tailor the medication which gives the best response with minimal side effects to each individual. |
DPIM Patient Information Sheet
DPIM Healthy Volunteer Information Sheet
|
PPiP2 - Pathogenic Antibodies in Psychosis
|
The PPiP2 study aims to investigate the prevalence of autoimmune antibodies in patients with psychosis and identify people with psychosis and anti-neuronal membrane antibodies to take part in the SINAPPS2 trial. |
Participation Information Sheet
The SINAPPS2 Clinical Trial - Treating psychosis with immunotherapy ? (video) - SINAPPS2 participant and family talking about their experience in the trial
SINAPPS Group (YouTube channel) (for Staff)
SINAPPS Research Group website (for Staff) -www.sinapps.org.uk
|
Recollect 2 - Recovery College Characterisation and Testing
|
The aim of RECOLLECT 2 is to develop the evidence base for Recovery Colleges in England and understand how they can provide the most benefit to people who use mental health services. Findings will help refine the previously developed RECOLLECT change model. This aim will be addressed through three studies.
|
RECOLLECT 2 Student Participant Information Sheet
|
WWW - Wellbeing While Waiting
|
The Wellbeing While Waiting study seeks to identify if there are benefits from offering social prescribing programmes to CYP on CAMHS waiting lists through undertaking observational research using questionnaires and interviews. |
WWW Parent-Guardian Information Sheet
WWW Participants 11-15 Information Sheet
WWW Participants 16-18 Information Sheet
|
Follow-up studies (no longer recruiting) :
CONNEX 3 - Treatment of Negative Symptoms in Schizophrenia |
CONNEX3 is a phase III randomized, double-blind, placebo-controlled trial to examine the efficacy and safety of Iclepertin |
M-CAMP (ID) - Multi-Component Anxiety Management Programme for People with Intellectual Disabilities |
There are an estimated 1.5 million people in England with an intellectual disability, with nearly half of people experiencing some difficulty with anxiety. The effect anxiety can have on a person’s life can be significant which can result in increased medication being prescribed to help the person cope with their mental health. For people who have a more severe intellectual disability and have difficulty with their communication, anxiety can be demonstrated through difficult behaviour, resulting in higher levels of medication being prescribed. There are not many effective therapies available that can help and support people with self-management of their anxiety. People with intellectual disabilities can develop these skills but need adapted therapies to develop and retain self-Management skills. There is some evidence which suggests that adapting therapies to help people with their anxiety can be effective, but this is limited to a single psychological therapy approach with no evidence of any long-term effects. Ove the last few years, a multidisciplinary team of CWP staff have worked with people who have an intellectual dis-ability and anxiety to co-produce a new anxiety management programme (which uses a range of different psycho-logical therapies) called ‘Brave’.
Publication: |
TONiC - Trajectories of Outcome in Neurological Conditions |
The Research behind the Questionnaire (MND)
|
